Reduced plasma taurine level in Parkinson's disease: association with motor severity and levodopa treatment

References

• Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947–54.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464–74.
   PubMed Web of Science ®Google Scholar
• Bianchi L, Colivicchi MA, Bolam JP, et al. The release of amino acids from rat neostriatum and substantia nigra in vivo: a dual microdialysis probe analysis. Neuroscience 1998;87:171–80.
   PubMed Web of Science ®Google Scholar
• Dray A, Straughan DW. Synaptic mechanisms in the substantia nigra. J Pharm Pharmacol 1976;28:400–5.
   PubMed Web of Science ®Google Scholar
• Palkovits M, Elekes I, Lang T, et al. Taurine levels in discrete brain nuclei of rats. J Neurochem 1986;47:1333–5.
   PubMed Web of Science ®Google Scholar
• Menzie J, Pan C, Prentice H, et al. Taurine and central nervous system disorders. Amino Acids 2014;46:31–46.
   PubMed Web of Science ®Google Scholar
• Yuan YS, Zhou XJ, Tong Q, et al. Change in plasma levels of amino acid neurotransmitters and its correlation with clinical heterogeneity in early Parkinson's disease patients. CNS Neurosci Ther 2013;19:889–96.
   PubMed Web of Science ®Google Scholar
• Engelborghs S, Marescau B, De Deyn PP. Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. Neurochem Res 2003;28:1145–50.
   PubMed Web of Science ®Google Scholar
• Molina JA, Jimenez-Jimenez FJ, Gomez P, et al. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J Neurol Sci 1997;150:123–7.
   PubMed Web of Science ®Google Scholar
• Alom J, Mahy JN, Brandi N, et al. Cerebrospinal fluid taurine in Alzheimer's disease. Ann Neurol 1991;30:735.
   PubMed Web of Science ®Google Scholar
• Arai H, Kobayashi K, Ichimiya Y, et al. A preliminary study of free amino acids in the postmortem temporal cortex from Alzheimer-type dementia patients. Neurobiol Aging 1984;5:319–21.
   PubMed Web of Science ®Google Scholar
• Huxtable RJ. Taurine in the central nervous system and the mammalian actions of taurine. Prog Neurobiol 1989;32:471–533.
   PubMed Web of Science ®Google Scholar
• Keep RF, Xiang J. Choroid plexus taurine transport. Brain Res 1996;715:17–24.
   PubMed Web of Science ®Google Scholar
• Bjerkenstedt L, Edman G, Hagenfeldt L, et al. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 1985;147:276–82.
   PubMed Web of Science ®Google Scholar
• Samuelsson M, Skogh E, Lundberg K, et al. Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia. Psychiatry Res 2013;210:819–24.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.
   PubMed Web of Science ®Google Scholar
• Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42.
   PubMed Web of Science ®Google Scholar
• Fahn S, Elton R, Members of the UPDRS Development Committee. The unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A, eds. Recent developments in Parkinson's disease. Florham Park (NJ): McMillan Health Care Information;1987:153–3.
   Google Scholar
• Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191–7.
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Visser M, Marinus J, Stiggelbout AM, et al. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Move Disord 2004;19:1306–12.
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Reynolds CF III, Monk TH, et al. Quantification of subjective sleep quality in healthy elderly men and women using the pittsburgh sleep quality index (PSQI). Sleep 1991;14:331–8.
   PubMed Web of Science ®Google Scholar
• Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol 2010;68:28–36.
   PubMed Web of Science ®Google Scholar
• Seet RC, Lee CY, Lim EC, et al. Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 2010;48:560–6.
   PubMed Web of Science ®Google Scholar
• O'Sullivan SS, Johnson M, Williams DR, et al. The effect of drug treatment on neurogenesis in Parkinson's disease. Move Disord 2011;26:45–50.
   PubMed Web of Science ®Google Scholar
• Wenzelburger R, Zhang BR, Pohle S, et al. Force overflow and levodopa-induced dyskinesias in Parkinson's disease. Brain 2002;125:871–9.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Abe T, Hashiguchi K, et al. A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degeneration. Neurosci Lett 1991;126:155–8.
   PubMed Web of Science ®Google Scholar
• Araki K, Takino T, Ida S, et al. Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degeneration. Acta Neurol Scand 1986;73:105–10.
   PubMed Web of Science ®Google Scholar
• Lakke JP, Teelken AW. Amino acid abnormalities in cerebrospinal fluid of patients with parkinsonism and extrapyramidal disorders. Neurology 1976;26:489–93.
   PubMed Web of Science ®Google Scholar
• Lakke JP, Teelken AW, vd Voet H, et al. Amino acid abnormalities in cerebrospinal fluid and blood serum of patients with Parkinson's disease, other heredodegenerative disorders and head injuries. Adv Neurol 1987;45:243–7.
   PubMedGoogle Scholar
• Dawson R Jr., Pelleymounter MA, Cullen MJ, et al. An age-related decline in striatal taurine is correlated with a loss of dopaminergic markers. Brain Res Bull 1999;48:319–24.
   PubMed Web of Science ®Google Scholar
• Tyce GM, Owen CA, Jr. The effect of L-3,4-dihydro-xyphenylalanine administration on glucose metabolism in brain. J Neurochem 1973;20:1563–73.
   PubMed Web of Science ®Google Scholar
• Biasetti M, Dawson R. Effects of sulfur containing amino acids on iron and nitric oxide stimulated catecholamine oxidation. Amino Acids 2002;22:351–68.
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B, Premovic PI, Sealy RC. Semiquinone anion radicals from addition of amino acids, peptides, and proteins to quinones derived from oxidation of catechols and catecholamines. An ESR spin stabilization study. J Biol Chem 1987;262:11080–7.
   PubMed Web of Science ®Google Scholar
• Muller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 2004;61:657–60.
   PubMed Web of Science ®Google Scholar
• Ahn CS. Effect of taurine supplementation on plasma homocysteine levels of the middle-aged Korean women. Adv Exp Med Biol 2009;643:415–22.
   PubMed Web of Science ®Google Scholar
• Yang HT, Chien YW, Tsen JH, et al. Taurine supplementation improves the utilization of sulfur-containing amino acids in rats continually administrated alcohol. J Nutr Biochem 2009;20:132–9.
   PubMed Web of Science ®Google Scholar
• Diederich C, Milakofsky L, Hare TA, et al. Effects of L-DOPA/carbidopa administration on the levels of L-DOPA, other amino acids and related compounds in the plasma, brain and heart of the rat. Pharmacology 1997;55:109–16.
   PubMed Web of Science ®Google Scholar